Europe Breast Cancer Screening Market is projected to grow US$ 433.5 Million by 2028

Renub Research has recently published a report named "Europe Breast Cancer Screening Market, Size, Forecast 2022-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" providing a detailed industry analysis that consists of market share insights. Furthermore, the report studies competitors and regions and the recent growth in the Europe Breast Cancer Screening Market.

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures:

The Europe Breast Cancer Screening Market is expected to experience a growth rate of approximately 3.19% from 2022 to 2028.At the moment, every European country provides some type of breast cancer screening. Nonetheless, there are differences in the state of implementation, attendance, and the scope of opportunistic screening. As a consequence, breast cancer screening has yet to fully realize its promise. Screening for breast, cervical, and colorectal cancer is recommended in the European Union when given as part of an organized program with enough resources for good quality. In the European Union, organized screening programs are encouraged since they employ a team of individuals who are responsible for ensuring the quality of the services supplied. This involves ensuring that rules are followed and that screening program findings are recorded and analysed on a regular basis.

The rising incidence of breast cancer, the existence of prominent companies in the European breast cancer screening market, and strong research and development are all driving the market's expansion. Breast cancer affects around 58,000 women and 380 men in the United Kingdom each year. Every year, about 47,000 individuals in England are diagnosed with breast cancer. Every year, around 4,800 individuals in Scotland are diagnosed with breast cancer. Every year, roughly 2,900 individuals in Wales are diagnosed with breast cancer. Breast cancer is the most frequent cancer among women in the European area; with a frequency of 565,500 in 2019, according to EUROPA DONNA, the European Coalition against Breast Cancer, and 1 in 8 women in the European countries will have breast cancer by the age of 85. As a result, breast cancer strikes many women at their prime years, which is expected to fuel market development throughout the projected period.

The German Breast Cancer Screening market has expanded dramatically as a result of growing breast cancer incidence and greater women's knowledge about early detection.

The difficulties of recognizing and treating cancers at late stages are driving up demand for early breast cancer diagnostics in Germany. The country's wealth of diagnostic facilities, together with a well-established healthcare system, contributes greatly to the growth. Furthermore, with roughly 70,000 new cases each year, breast cancer is the most frequent cancer form among women in Germany. Despite breakthroughs in therapy, breast cancer still takes over 17,000 lives each year, emphasizing the need of comprehensive screening programs.While imaging and screening technologies have grown in popularity, the safety and accuracy of certain treatments are still being questioned for long-term usage. Due to a lack of evidence supporting its dependability and cost, genomic testing, next-generation sequencing, and blood tests have lower demand than imaging. Breast biopsy for diagnosis is predicted to gain prominence over time. The growing number of breast cancer patients, the development of cost-effective diagnostic methods, favourable government reimbursement policies, and the expansion of private diagnostic facilities are all projected to increase the German breast cancer diagnostics market.

Increasing consciousness, growing breast cancer incidence, and better healthcare infrastructure are the primary drivers driving the expansion of the Breast cancer mammography screening sector in Spain.

In Spain, breast cancer mammography screening is a vital part of healthcare, aiming for early detection and better outcomes for patients. X-rays are used to examine the breast for any cancer signs in women without symptoms. The program focuses on women aged 50-69, at higher risk. Success depends on awareness, accessibility to facilities, and support from the healthcare system and government. Regular screening is crucial for early detection, leading to improved treatment options and survival rates. Advancements in technology like digital mammography and 3D tomosynthesis enhance accuracy and efficiency in breast cancer detection.

The United Kingdom is experiencing significant growth in the Breast Cancer MRI Screening industry.

The United Kingdom (UK) is seeing substantial expansion in the Breast Cancer MRI Screening business. As knowledge about breast cancer and the need of early detection improves, more women are choosing for MRI tests. The UK's healthcare infrastructure and availability to innovative medical technology contribute to the market's development. MRI screens provide greater accuracy and sensitivity in identifying breast cancer, leading to better results for patients. With continued developments in MRI technology and greater focus on preventive healthcare, the UK is positioned as a fast developing market in breast cancer MRI screening, benefitting both patients and healthcare providers.

The Germany Breast Cancer Ultrasound Industry is undergoing remarkable expansion.

Germany's well-developed healthcare infrastructure and devotion to patient care have further encouraged the acceptance of breast cancer ultrasonography. Healthcare practitioners are increasingly depending on ultrasound-guided biopsies to collect exact tissue samples for proper diagnosis and therapy planning. The industry's development is also fuelled by an increasing focus on breast cancer awareness and frequent screening efforts. More women understand the value of early diagnosis, leading to rising demand for breast cancer ultrasound tests. Continuous research and improvements in ultrasound technology are boosting picture quality and diagnostic capabilities, further supporting the industry's prospects in Germany.

Key Player

In the Europe Breast Cancer Screening Market, important firms such as AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc have substantial positions.

Types – Market has been covered from 3 viewpoints (Mammography Screening, MRI Screening and Ultrasound Screening)

Countries – 8 European Country Breast Cancer Screening Market has been Covered (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands)

Company Insights: (Overview, Recent Development &Sales Analysis)

Companies Covered in the Report: (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc)

Related Reports

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: [email protected]

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com